Checkpoint Therapeutics, Inc.
3 clinical trials · Sponsor
◉ Watch Checkpoint Therapeutics, Inc.
| Record | Firm | Date |
|---|---|---|
| Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC (NCT04786964) | Checkpoint Therapeutics, Inc. | 2021-12-08 |
| Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers (NCT03212404) | Checkpoint Therapeutics, Inc. | 2017-09-20 |
Track Checkpoint Therapeutics, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.